免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：info@selleck.cn

R406

目录号：S2194

仅限科研使用

R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。

CAS: 841290-81-1

规格	价格	库存
10mM (1mL in DMSO)	RMB 2341.19	现货
5mg	RMB 1421.87	现货
50mg	RMB 7119.85	现货
大包装	有超大折扣
大剂量询单有大折扣!
今日订购，明日送达全国免运费分装免费分装成小规格产品（单支最小为1mg）如1支10mg产品可分装为10支1mg产品全国免费电话：400-668-6834 \| Email：info@selleck.cn

客户使用Selleck生产的R406发表文献89篇：

产品安全说明书

Syk抑制剂选择性比较

生物活性

产品描述

R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。

特性

Rigel选择R406作为治疗风湿性关节炎的潜在领先药物。

靶点

Flt3 ^[1] (Cell-free assay)	Syk ^[1] (Cell-free assay)
	41 nM

体外研究

R406强抑制免疫球蛋白 E (IgE)和 IgG调节的受体信号活性。R406抑制IgE抗体诱导的 LTC4 ，细胞因子和趋化因子的产生和释放, 包括TNFα, IL-8, 和GM-CSF。R406 抑制肥大细胞中T细胞Syk底物链接蛋白的激活和B细胞中B细胞链接蛋白/SLP65的磷酸化作用。R406 结合到Syk的ATP结合袋中，抑制Syk的激酶活性， R406是ATP竞争性抑制剂，K_i为30 nM。R406阻断单核细胞/巨噬细胞和中性白细胞中Syk依赖的FcR调节活性，且阻断B淋巴细胞中BCR调节活性。^[1]406 明显诱导慢性淋巴细胞白血病（CCL）细胞凋亡，且阻断CCL3和CCL4 分泌。^[2] R406有效抑制血小板信号，且抑制使用特殊抗体或 HIT 病患的血浆通过FcγRIIA 交叉结合形成的功能。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

AMO-1	MUTGeY5kfGmxbjDBd5NigQ>?	M1zINVEh\|ryP	MoHSN:KhcA>?		NH3WbWFz\WS3Y3XzJI1q\3KjdHnvcuKh	NHPodYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NVc3OSd-Mk[yOVE4PjF:L3G+
U266	M3XVemZ2dmO2aX;uJGF{e2G7	NIPZT2MyKM7:TR?=	MnjGN:KhcA>?		M{D2W5Jm\HWlZYOgcYloemG2aX;uxsA>	NG\QdFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NVc3OSd-Mk[yOVE4PjF:L3G+
Jeko-1	NVG3[2VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUG0PEBp		NX;HVXFRUUN3ME21MlA3QDJ4IN88US=>	M375dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1O\|U2Lz5{NUizOVc2PTxxYU6=
Mino	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnLqOFghcA>?		NXTCVnhIUUN3ME21MlcxQDV2IN88US=>	M{i1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1O\|U2Lz5{NUizOVc2PTxxYU6=
Jeko-1	NHO4Z3BCeG:ydH;zbZMhSXO\|YYm=	MkLLOeKh\|ryP	NVvYWWQ{OjRiaB?=		Moj4bY5lfWOnczCyOU4yyqEEsdMgN{4zyqBnIHHwc5B1d3Orcx?=	M1;IOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1O\|U2Lz5{NUizOVc2PTxxYU6=
primary MCL	MVPBdI9xfG:\|aYOgRZN{[Xl?	MkX6NkDDvU1?	MnzPNlQhcA>?		MkD2bY5kemWjc3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m\|wrC=	NFK3PI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFM4Oyd-MkWzPFg{PzN:L3G+
PBMCs	NHnMeXFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NX33co04OC13MDFOwG0>	NInPdpczPCCq	MUjEUXNQ	MnfrbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMke4OlIoRjJ3MUK3PFYzRC:jPh?=
PBMCs	NHKxTIRHfW6ldHnvckBCe3OjeR?=	NIflWYM2KM7:TR?=	NYezVnd{OSCq	Mmj3SG1UVw>?	NXLiR\|l{\GWlcnXhd4V{KHSqZTDj[YxtKG2rZ4LheIlwdg>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{N{i2Nkc,OjVzMke4OlI9N2F-
CFSE-CD4+ T	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYWwMlA3OjVvMTFOwG0>	MnzsOEBl		NYjEZYRM[myxY3vzJJBzd2yrZnXyZZRqd25ib3[gS3ZJTC2mZYLpeoVlKEOGNDxCpHQh[2WubIOgZY5lKEOGMUHiL:Kh[2WubIO=	M{PJTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke5PVgzLz5{NE[3PVk5OjxxYU6=
CFSE-CD11b+	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqwMlA3OjVvMTFOwG0>	M3T1fVgh\A>?		NGPzPXNjdG:la4OgdJJwdGmoZYLheIlwdiCxZjDHWmhFNWSncnn2[YQhS0R2K9MgWEBk\WyuczDhcoQhS0RzMXKrxsBk\Wyucx?=	M3XsVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke5PVgzLz5{NE[3PVk5OjxxYU6=
HMECs	Mo\RSpVv[3Srb36gRZN{[Xl?	Mn;HNE0yOCEQvF2=	NW\FVJN5OjBibXnu		M3HUTYlvcGmkaYTzJHZGT0Zvc4TpcZVt[XSnZDDy[Yxm[XOnIH;mJG5Q	NYn6bnc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlk2PDRpPkK0N\|I6PTR2PD;hQi=>
AB5	NITRS\|VCeG:ydH;zbZMhSXO\|YYm=	NHH1fZkxNTJwNTFOwG0>	NFy5VXo1QCCq	MXrEUXNQ	M37kbYlv\HWlZYOgZZBweHSxc3nz	NUjCW\|hPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN\|k5QTFzPD;hQi=>
JB7	NInmTnVCeG:ydH;zbZMhSXO\|YYm=	NHXVc2gxNTJwNTFOwG0>	MXe0PEBp	MYfEUXNQ	NX\FfHNlcW6mdXPld{BieG:ydH;zbZM>	NGHXOoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5PFkyOSd-MkOzPVg6OTF:L3G+
AB5	NHTzdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LZd\|AuOi53IN88US=>	M3rVcVQ5KGh?	MV3EUXNQ	M3fROIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NU[5SG1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN\|k5QTFzPD;hQi=>
JB7	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\mRll6OC1{LkWg{txO	MVK0PEBp	NX\VfIx1TE2VTx?=	M2TKR4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NFTheng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5PFkyOSd-MkOzPVg6OTF:L3G+
RL	M3n2O2Z2dmO2aX;uJGF{e2G7	MkfwNk42NzVizszN	NGXBWJIzPC92ODDo	M4XrO2ROW09?	NH3yPZNqdmS3Y3XzJIEheG:2ZX70JIRm[3KnYYPlJIlvKE2PUD25JI1TVkFiZYjwdoV{e2mxbh?=	NWTZOnB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlY6PjVpPkKxPVI3QTZ3PD;hQi=>
RL	NGG2TpBHfW6ldHnvckBCe3OjeR?=	M17H[lEwOi53IN88US=>	MmjlNlQhcA>?	MXnEUXNQ	MUTy[YR2[2W\|IITo[UBi[3SrdnH0bY9vKG:oIFHreEBidmRicEewV\|ZM	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{Nkm2OUc,OjF7Mk[5OlU9N2F-
platelet	MmfySpVv[3Srb36gRZN{[Xl?	NFnROlMyyqEQvH2=	MlXTOUBucW5?		NYjoepN1cW6qaXLpeJMhTmQQs2LJTWEudWWmaXH0[YQheGyjdHXs[ZQh[WepcnXnZZRqd25?	NVPFfZF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OFg3QTRpPkKxPFQ5Pjl2PD;hQi=>
platelet	MX3GeY5kfGmxbjDBd5NigQ>?	NVPabo9EOC5yNT:xM\|IvPSEQvF2=	NF\NN3E2KG2rbh?=		NFnad4ZqdmirYnn0d{B1cGVic3nncoFtcW6pIH3lZ4hidmm\|bYOg[I94dnO2cnXhcUBw\iCIY98zVmlKSQ>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh2OE[5OEc,OjF6NEi2PVQ9N2F-
DoHH2	MX3BdI9xfG:\|aYOgRZN{[Xl?	M3zPPVAwOy9zMDFOwG0>	NWHnc\|EyPDhiaB?=		M3rrVYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7	M3Tab\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1OFA5Lz5{MEi3OVQxQDxxYU6=
Jeko-1	MmHaRZBweHSxc3nzJGF{e2G7	Mkm5NE8{NzFyIN88US=>	MlPGOFghcA>?		MnXLbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHl?	M2i4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1OFA5Lz5{MEi3OVQxQDxxYU6=
Raji	M3X5NGFxd3C2b4Ppd{BCe3OjeR?=	MYGwM\|MwOTBizszN	NEewUmo1QCCq		NEK0[IxqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?=	NYe4[XM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|U1ODhpPkKwPFc2PDB6PD;hQi=>
DHL4	NWTDTIc6SXCxcITvd4l{KEG\|c3H5	M1rqeVAwOS92IN88US=>	NEHKcnc6PiCq		NGrQbHhqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M1jYOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY7	MkH1RZBweHSxc3nzJGF{e2G7	NHPDPW4xNzFxNDFOwG0>	MWK5OkBp		NVjuSnZ5cW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY3	MlnORZBweHSxc3nzJGF{e2G7	M3;sRVAwOS92IN88US=>	MXK5OkBp		MVrpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NGHET2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL6	Mn7xRZBweHSxc3nzJGF{e2G7	M2PZbVAwOS92IN88US=>	NV\XdmpbQTZiaB?=		MUTpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	M4rYd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY10	MULBdI9xfG:\|aYOgRZN{[Xl?	M4OyUlAwOS92IN88US=>	M4j3Vlk3KGh?		MYjpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
DHL10	MV7BdI9xfG:\|aYOgRZN{[Xl?	MVywM\|EwPCEQvF2=	NF;jb\|k6PiCq		NH3jRoFqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	NV7DdWxlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
Wsu-NHL	NUH4ZXJkSXCxcITvd4l{KEG\|c3H5	NGO2epcxNzFxNDFOwG0>	M1Twc\|k3KGh?		MofYbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	NUPaToxRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY18	NXHRfmtySXCxcITvd4l{KEG\|c3H5	NVy2VGJvOC9zL{Sg{txO	M{\wZ\|k3KGh?		NF7TO5hqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M{T6O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY1	NU\5V5VGSXCxcITvd4l{KEG\|c3H5	NID2U2gxNzFxNDFOwG0>	M3K2TVk3KGh?		NUi3XHBGcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	M1LJNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL8	MXzBdI9xfG:\|aYOgRZN{[Xl?	NFzDPGUxNzFxNDFOwG0>	NHLZcms6PiCq		NILheohqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	NF7acVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL4	MWrBdI9xfG:\|aYOgRZN{[Xl?	MmfqOEDPxE1?	NXzRd2R{QTZiaB?=		NY[2cYhDcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmeyB7IHHu[EA{NCCkdYSgco91KGOjc4Dhd4UhQA>?	M3PCOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL6	MoW1RZBweHSxc3nzJGF{e2G7	NIPCfVM1KM7:TR?=	M4nBXlk3KGh?		MVrpcoR2[2W\|IHPs[YF3[WenIH;mJINie3Cjc3XzJFkh[W6mIEOsJIJ2fCCwb4SgZ4F{eGG\|ZTC4	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY3	MXXBdI9xfG:\|aYOgRZN{[Xl?	M2TifFQh\|ryP	NH\GVYw6PiCq		MlrobY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{A6KGGwZDCzMEBjfXRibn;0JINie3Cjc3WgPC=>	NFXvd3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
LY7	MnLPRZBweHSxc3nzJGF{e2G7	M1rS[lQh\|ryP	NInOfXQ6PiCq		NH7DVYVqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{KDliYX7kJFMtKGK3dDDuc5Qh[2G\|cHHz[UA5	NF[1Tms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL4	NUT4Um1CTnWwY4Tpc44hSXO\|YYm=	NHf3[Xo1KM7:TR?=	NVXESVBxOTZiaB?=		M3K2NolvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	NH3IUVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
LY7	MoDNSpVv[3Srb36gRZN{[Xl?	MnHzOEDPxE1?	NWjCZXV{OTZiaB?=		M4TBUYlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	MnTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY3	NYGxZ\|NyTnWwY4Tpc44hSXO\|YYm=	MVi0JO69VQ>?	M1PxcFE3KGh?		M{TtUYlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
DHL6	NFz0ZVBHfW6ldHnvckBCe3OjeR?=	M1zIWFQh\|ryP	NVzscWk3OTZiaB?=		NILUVFJqdmirYnn0d{B1d26rYzDCUG5MKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvci=>	MkXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY10	M3HJdGZ2dmO2aX;uJGF{e2G7	NVLkN4d7PCEQvF2=	NVPUeoRDOTZiaB?=		MVPpcohq[mm2czD0c45q[yCETF7LJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbh?=	NYnXO21NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
Wsu-NHL	NVu5V\|dETnWwY4Tpc44hSXO\|YYm=	MXS0JO69VQ>?	NX\W[\|hmOTZiaB?=		M2HjdIlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	NYjYbFdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY18	NG\nS\|BHfW6ldHnvckBCe3OjeR?=	NFXvTlM1KM7:TR?=	MnS2NVYhcA>?		NFznOHVqdmirYnn0d{B1d26rYzDCUG5MKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvci=>	NXfuSIRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
MV411	NFPnW3NHfW6ldHnvckBie3OjeR?=		MVK3NkBpenN?		NWW1PWxOUW6qaXLpeIlwdiCxZjDGcJQ{KGmwIHj1cYFvKE2YNEGxJINmdGy\|IHHzd4V{e2WmIHHzJIF{e2W\|c3XkJIF{KHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGmwY4XiZZRqd25iYomgd5Bm[3S{b4Doc5RwdWW2comsJGVEPTB;MD6wNe69VS5?	NX\mbopoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
TF1	NH3SXHJHfW6ldHnvckBie3OjeR?=		M13CXlEhcHJ?		M37RbWlvcGmkaYTpc44hd2ZiSnHrNkBqdiCncon0bJJweG:rZYTpck1{fGmvdXzheIVlKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCjc4Pld5Nm\CCjczDwbI9{eGixLWP0ZZQ2KGGodHXyJFEhcHJiaX7jeYJifGmxbjygSWM2OD1yLkCxN:69VS5?	NIjPVm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3PVUyPCd-MkS3O\|k2OTR:L3G+
neutrophils	MkH2SpVv[3Srb36gZZN{[Xl?				MkLXTY5pcWKrdHnvckBw\iCVWVugbY4hcHWvYX6gcoV2fHKxcHjpcJMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIF\j[ZB{cWyxbmKxM2Zk\2GvbXHSMY1m\GmjdHXkJJNq\26jbHnu[{Bz\XOyb37z[ZMtKEWFNUC9NE4xOzQQvF2u	NHv1TZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK1O\|IyOyd-MkKyOVczOTN:L3G+
SK-M-MC	M1T3O2Z2dmO2aX;uJIF{e2G7		MX6xJIhz		NVTjPGFpUW6qaXLpeIlwdiCxZjDS[ZQhcW5iaIXtZY4hW0tvTT3NR{Bk\WyuczDhd5Nme3OnZDDhd{Bie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44h[W[2ZYKgNUBpeiCrbnP1ZoF1cW:wLDDFR\|UxRTBwMEO2{txONg>?	M1TEUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{e5OVE1Lz5{NEe3PVUyPDxxYU6=
mast cells	MYHGeY5kfGmxbjDhd5NigQ>?		MkTzNUBpeg>?		Ml;jTY5pcWKrdHnvckBw\iClS3n0JIlvKHO2ZX2gZ4VtdCCoYXP0c5Iue3SrbYXsZZRm\CCkb37lJI1ienKxdzDk[ZJqfmWmIH3veZNmKG2jc4SgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIHHmeIVzKDFiaIKgbY5kfWKjdHnvckwhTUN3ME2wMlA1Ps7:TT6=	M3izZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{e5OVE1Lz5{NEe3PVUyPDxxYU6=
B-cells	M{TWbmZ2dmO2aX;uJIF{e2G7				NF\DWphKdmirYnn0bY9vKG:oIGPZT{BqdiCqdX3hckBDNWOnbHzzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCIY3Xwd4ltd26UMT;GZ4didW2jUj3t[YRq[XSnZDDzbYdv[WyrbnegdoV{eG:wc3XzMEBGSzVyPUCuNFQ5\|ryPLh?=	M2j5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkW3NlE{Lz5{MkK1O\|IyOzxxYU6=
Ramos	MYTGeY5kfGmxbjDhd5NigQ>?				NXnEVIpDUW6qaXLpeIlwdiCxZjDTfYshcW5iYX70bYh2dWGwIFnnUU1{fGmvdXzheIVlKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGJEWi2vZXTpZZRm\CCETF7LJJBpd3OyaH;yfYxifGmxbjDifUBk\WyudXzhdkBie3OjeTygSWM2OD1yLkC1N:69VS5?	MlHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
mesangial cells	M3HUNWZ2dmO2aX;uJIF{e2G7				Mon0TY5pcWKrdHnvckBw\iCVWVugbY4h[3WudIXy[YQhcHWvYX6gcYV{[W6paXHsJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCIY3Xwd4ltd26UMT;GZ4didW2jUj3t[YRq[XSnZDDzbYdv[WyrbnegdoV{eG:wc3XzMEBGSzVyPUCuNFU3\|ryPLh?=	NW\vU\|MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF\|PD;hQi=>
SK-N-SH	NITmcJdHfW6ldHnvckBie3OjeR?=				M4\DV2lvcGmkaYTpc44hd2ZiUnX0JIlvKGi3bXHuJHNMNU5vU1igZ4VtdHNuIFXDOVA:OC5yON88UU4>	NW\NNVloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF\|PD;hQi=>
mouse bone marrow cells	NIPJTnVHfW6ldHnvckBie3OjeR?=				MmX4TY5pcWKrdHnvckBw\iCLTEOg[IVx\W6mZX70JJBzd2yrZnXyZZRqd25iaX6gR\|U4N0JzNjDtc5V{\SCkb37lJI1ienKxdzDj[YxteyC3c3nu[{BcO0ifdHj5cYllcW6nIHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwQVAvOTR5zszNMi=>	NX7tWoNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODZpPkK0O\|I3QDB4PD;hQi=>
B-cells	NV\YdXFpTnWwY4Tpc44h[XO\|YYm=		MUKxJIhz		NGHibZpKdmirYnn0bY9vKG:oIGP5b{BqdiCjbIDoZWloVS2\|dHnteYxifGWmIHj1cYFvKEJiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDFiaIKgbY5kfWKjdHnvckBjgSCobH;3JIN6fG:vZYTyfUwhTUN3ME2wMlE2Oc7:TT6=	NUjiT5lxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
THP1	MW\GeY5kfGmxbjDhd5NigQ>?				M3rneGlvcGmkaYTpc44hd2ZiU2nLJIlvKGi3bXHuJHRJWDFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGZk\XC\|aXzvcnIyN0[lZ3HtcYFTNW2nZHnheIVlKHOrZ37hcIlv\yC{ZYPwc45{\XNuIFXDOVA:OC5zN{JOwG0v	NXf0Z4tPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF\|PD;hQi=>
B-cells	NUTtOYVnTnWwY4Tpc44h[XO\|YYm=		M4f6flEhcHJ?		Ml:1TY5pcWKrdHnvckBw\iCVeXugbY4h[WyyaHHJ[20ue3SrbYXsZZRm\CCqdX3hckBDKGOnbHzzJIF{e2W\|c3XkJIF{KEOGOE[g[ZhxemW\|c3nvckBi\nSncjCxJIhzKGmwY4XiZZRqd25iYomg[oxwfyCleYTvcYV1enluIFXDOVA:OC5\|M{ZOwG0v	NYDVUmJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
Ramos	MVvGeY5kfGmxbjDhd5NigQ>?				NYjOXVJWUW6qaXLpeIlwdiCxZjDTfYshcW5iYX70bUBK\01vc4TpcZVt[XSnZDDoeY1idiCUYX3vd{Bk\WyuczDhd5Nme3OnZDDhd{BDVE6NIIDoc5NxcG:{eXzheIlwdiCkeTDj[YxtfWyjcjDhd5NigSxiSVO1NF0xNjR3N988UU4>	NWjQVWYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODZpPkK0O\|I3QDB4PD;hQi=>
Rec1	NFLidVRHfW6ldHnvckBie3OjeR?=	NIjjRngzNjVidV2=	Mk\0OkBpenN?		NILqXoRKdmirYnn0bY9vKG:oIFLUT{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>?	M3jUR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKyPFc4Lz5{NUKyNlg4PzxxYU6=
Rec1	MYXGeY5kfGmxbjDhd5NigQ>?	MkPUNk42KHWP	MUS2JIhzew>?		NHzvc2JKdmirYnn0bY9vKG:oIGP5b{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>?	MnrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkK4O\|coRjJ3MkKyPFc4RC:jPh?=
Rec1	NYXR[lZVTnWwY4Tpc44h[XO\|YYm=	NEfZ[JozNjVidV2=	MUG2JIhzew>?		M1fkVmlvcGmkaYTpc44hd2ZiTInuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDS[YMyKGOnbHzzJIF1KDJwNTD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
SJ-GBM2	MX;xTHRUKGG\|c3H5				NUPEfGpNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NFruXGVyUFSVIHHzd4F6				M{TpW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MoOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	Mn24dWhVWyCjc4PhfS=>				NUTFVIc3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NVfBPWZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NVzWRnN{eUiWUzDhd5NigQ>?				M3HBUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MVnxTHRUKGG\|c3H5				NWjTUYVreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NFPYNWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	MlrydWhVWyCjc4PhfS=>				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	NF3CS\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NWm1NGp5eUiWUzDhd5NigQ>?				NUTMNJN5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	M2XSZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-RPS6 / T-RPS6 / p-4E-BP1 / T-4E-BP1 p-MEK / T-MEK / p-ERK / T-ERK p-c-RAF / T-c-RAF p-AKT / T-AKT / p-mTOR / T-mTOR	23535559
Growth inhibition assay	Cell viability (U87, U251 cells) Cell viability (GSC lines)	31043589

体内研究

在已经预防处理的鼠内进行阳性Arthus 反应，5 mg/kg R406诱导鼠皮肤病变达到86%。R406作用于抗体诱导的关节炎鼠模型，也有效抑制炎症。^[1] 自身免疫反应时，R406不会影响巨噬细胞和嗜中性粒细胞的功能，免疫毒性为最低水平。^[3]

动物实验：^[1]	Animal Models: 在C57BL/6鼠中腹腔注射150 μL 取自成年K/BxN鼠的混合血清诱导产生关节炎。 Dosages: 1 或5 mg/kg Administration: 口服处理

参考文献	[1] Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008. [2] Quiroga MP, et al. Blood, 2009, 114(5), 1029-1037. [3] Lhermusier T, et al. J Thromb Haemost, 2011, 9(10), 2067-2076. [4] Zhu Y, et al. Toxicol Appl Pharmacol, 2007, 221(3), 268-277. + 展开

溶解度（25°C）

体外


体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%dmso+95%cornoil 点击购买： Corn Oil	6mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量	628.63
化学式	C₂₂H₂₃FN₆O₅.C₆H₆O₃S
CAS号	841290-81-1
储存条件	3年	-20°C	粉状
储存条件	2年	-80°C	溶于溶剂

Download R406 SDF

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

临床试验信息

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01725230	Completed	Drug: Fostamatinib\|Drug: Rosuvastatin\|Drug: Simvastatin	Rheumatoid Arthritis	AstraZeneca	November 2012	Phase 1
NCT01598571	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	May 2012	Phase 1
NCT01387308	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	August 2011	Phase 1
NCT01355354	Completed	Drug: Digoxin\|Drug: Fostamatinib	Healthy Volunteers\|Rheumatoid Arthritis	AstraZeneca	June 2011	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

常见问题及建议解决方法

问题 1:
What’s the difference between S1533 and S2194?

回答：
S1533 and S2194 are two different forms of R406. S1533 is the free base form, containing only R406 molecule without a acid added to it. S2194 has an additional C6H6O3S acid on it which makes the molecule a salt form. The free base and salt forms have same biology activities. Free base has a lower molecular weight and salt form has a better solubility in DMSO.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):